XML 53 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

Segments of business and geographic areas (Tables) | 9 Months Ended
--- | ---
Sep. 28, 2025
Segment Reporting [Abstract] |
Sales By Segment Of Business |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $3,468 |  | 2,816 |  | 23.2 | % |  | $9,866 |  | 7,835 |  | 25.9 | %
International |  | 3,060 |  | 2,565 |  | 19.3 |  |  | 8,652 |  | 7,450 |  | 16.1 |
Worldwide |  | 6,529 |  | 5,380 |  | 21.3 |  |  | 18,519 |  | 15,284 |  | 21.2 |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 396 |  | 258 |  | 53.3 |  | 1,072 |  | 565 |  | 89.6
International |  | 128 |  | 27 |  | * |  | 260 |  | 63 |  | *
Worldwide |  | 524 |  | 286 |  | 83.5 |  | 1,332 |  | 629 |  | *
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,088 |  | 1,684 |  | 24.0 |  |  | 5,934 |  | 4,789 |  | 23.9 |
International |  | 1,584 |  | 1,332 |  | 18.9 |  |  | 4,514 |  | 3,797 |  | 18.9 |
Worldwide |  | 3,672 |  | 3,016 |  | 21.7 |  |  | 10,448 |  | 8,586 |  | 21.7 |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 378 |  | 337 |  | 12.3 |  |  | 1,048 |  | 940 |  | 11.5 |
International |  | 558 |  | 453 |  | 23.0 |  |  | 1,567 |  | 1,275 |  | 22.9 |
Worldwide |  | 936 |  | 790 |  | 18.4 |  |  | 2,615 |  | 2,215 |  | 18.0 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 211 |  | 259 |  | (18.3) |  |  | 685 |  | 770 |  | (11.0) |
International |  | 483 |  | 494 |  | (2.3) |  |  | 1,453 |  | 1,537 |  | (5.4) |
Worldwide |  | 695 |  | 753 |  | (7.8) |  |  | 2,139 |  | 2,307 |  | (7.3) |
RYBREVANT/ LAZCLUZE(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 136 |  | 68 |  | 99.7 |  | 388 |  | 156 |  | *
International |  | 61 |  | 21 |  | * |  | 130 |  | 49 |  | *
Worldwide |  | 198 |  | 89 |  | * |  | 518 |  | 205 |  | *
TALVEY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 85 |  | 64 |  | 34.2 |  |  | 235 |  | 173 |  | 35.8 |
International |  | 37 |  | 12 |  | * |  | 79 |  | 29 |  | *
Worldwide |  | 122 |  | 75 |  | 60.8 |  |  | 314 |  | 202 |  | 55.3 |
TECVAYLI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 115 |  | 105 |  | 9.3 |  |  | 334 |  | 310 |  | 7.5 |
International |  | 62 |  | 30 |  | * |  | 160 |  | 93 |  | 73.0 |
Worldwide |  | 177 |  | 135 |  | 31.3 |  |  | 494 |  | 403 |  | 22.6 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 5 |  | 5 |  | (25.0) |  |  | 18 |  | 25 |  | (30.4) |
International |  | 108 |  | 144 |  | (25.1) |  |  | 365 |  | 470 |  | (22.3) |
Worldwide |  | 113 |  | 150 |  | (25.1) |  |  | 383 |  | 496 |  | (22.8) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 56 |  | 36 |  | 54.6 |  |  | 153 |  | 106 |  | 44.8 |
International |  | 39 |  | 50 |  | (22.2) |  |  | 123 |  | 136 |  | (9.7) |
Worldwide |  | 94 |  | 86 |  | 9.7 |  |  | 276 |  | 242 |  | 14.0 |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,676 |  | 3,068 |  | (12.8) |  |  | 7,377 |  | 8,499 |  | (13.2) |
International |  | 1,493 |  | 1,552 |  | (3.9) |  |  | 4,492 |  | 5,090 |  | (11.8) |
Worldwide |  | 4,168 |  | 4,621 |  | (9.8) |  |  | 11,868 |  | 13,590 |  | (12.7) |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 326 |  | 281 |  | 16.2 |  |  | 923 |  | 778 |  | 18.7 |
U.S. Exports |  | 19 |  | 27 |  | (30.9) |  |  | 63 |  | 89 |  | (29.6) |
International |  | 132 |  | 112 |  | 17.7 |  |  | 413 |  | 380 |  | 8.6 |
Worldwide |  | 476 |  | 419 |  | 13.6 |  |  | 1,398 |  | 1,246 |  | 12.2 |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 309 |  | 299 |  | 3.6 |  |  | 906 |  | 820 |  | 10.5 |
International |  | 377 |  | 218 |  | 73.0 |  |  | 1,130 |  | 787 |  | 43.5 |
Worldwide |  | 687 |  | 516 |  | 32.9 |  |  | 2,036 |  | 1,607 |  | 26.7 |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,022 |  | 1,770 |  | (42.3) |  |  | 3,081 |  | 5,021 |  | (38.6) |
International |  | 549 |  | 906 |  | (39.4) |  |  | 1,768 |  | 2,991 |  | (40.9) |
Worldwide |  | 1,570 |  | 2,676 |  | (41.3) |  |  | 4,848 |  | 8,012 |  | (39.5) |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 989 |  | 691 |  | 43.1 |  |  | 2,384 |  | 1,789 |  | 33.3 |
International |  | 434 |  | 316 |  | 37.4 |  |  | 1,181 |  | 932 |  | 26.7 |
Worldwide |  | 1,424 |  | 1,007 |  | 41.3 |  |  | 3,566 |  | 2,721 |  | 31.0 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 12 |  | 1 |  | * |  | 21 |  | 3 |  | *
International |  | 0 |  | 0 |  | — |  | 0 |  | 0 |  | —
Worldwide |  | 12 |  | 1 |  | * |  | 21 |  | 3 |  | *
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,367 |  | 1,094 |  | 25.0 |  |  | 3,712 |  | 3,250 |  | 14.2 |
International |  | 658 |  | 662 |  | (0.7) |  |  | 2,011 |  | 2,090 |  | (3.8) |
Worldwide |  | 2,024 |  | 1,755 |  | 15.3 |  |  | 5,722 |  | 5,340 |  | 7.2 |
CAPLYTA(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 240 |  | — |  | * |  | 451 |  | — |  | *
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 240 |  | — |  | * |  | 451 |  | — |  | *
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 14 |  | 26 |  | (49.2) |  |  | 76 |  | 101 |  | (24.9) |
International |  | 127 |  | 117 |  | 9.0 |  |  | 376 |  | 382 |  | (1.4) |
Worldwide |  | 140 |  | 142 |  | (1.4) |  |  | 452 |  | 482 |  | (6.3) |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 664 |  | 780 |  | (14.9) |  |  | 2,021 |  | 2,329 |  | (13.2) |
International |  | 267 |  | 269 |  | (0.9) |  |  | 804 |  | 830 |  | (3.1) |
Worldwide |  | 929 |  | 1,049 |  | (11.3) |  |  | 2,824 |  | 3,159 |  | (10.6) |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 405 |  | 243 |  | 67.1 |  |  | 1,047 |  | 660 |  | 58.7 |
International |  | 53 |  | 42 |  | 28.9 |  |  | 146 |  | 120 |  | 21.9 |
Worldwide |  | 459 |  | 284 |  | 61.5 |  |  | 1,193 |  | 780 |  | 53.0 |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 46 |  | 46 |  | 0.4 |  |  | 119 |  | 161 |  | (26.4) |
International |  | 210 |  | 235 |  | (10.7) |  |  | 684 |  | 759 |  | (9.8) |
Worldwide |  | 256 |  | 281 |  | (8.9) |  |  | 803 |  | 920 |  | (12.7) |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 815 |  | 815 |  | (0.1) |  |  | 2,358 |  | 2,324 |  | 1.5 |
International |  | 300 |  | 287 |  | 4.8 |  |  | 895 |  | 866 |  | 3.4 |
Worldwide |  | 1,115 |  | 1,102 |  | 1.1 |  |  | 3,253 |  | 3,190 |  | 2.0 |
OPSUMIT/OPSYNVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 409 |  | 417 |  | (1.6) |  |  | 1,175 |  | 1,149 |  | 2.3 |
International |  | 168 |  | 166 |  | 1.1 |  |  | 507 |  | 506 |  | 0.2 |
Worldwide |  | 578 |  | 583 |  | (0.8) |  |  | 1,682 |  | 1,655 |  | 1.7 |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 392 |  | 379 |  | 3.5 |  |  | 1,139 |  | 1,120 |  | 1.7 |
International |  | 92 |  | 80 |  | 15.2 |  |  | 272 |  | 232 |  | 17.0 |
Worldwide |  | 484 |  | 458 |  | 5.6 |  |  | 1,411 |  | 1,352 |  | 4.3 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 13 |  | 21 |  | (36.5) |  |  | 44 |  | 56 |  | (21.5) |
International |  | 39 |  | 39 |  | (1.0) |  |  | 116 |  | 127 |  | (8.9) |
Worldwide |  | 53 |  | 60 |  | (13.1) |  |  | 160 |  | 183 |  | (12.7) |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 326 |  | 365 |  | (10.5) |  |  | 961 |  | 1,023 |  | (6.0) |
International |  | 501 |  | 471 |  | 6.4 |  |  | 1,472 |  | 1,599 |  | (7.9) |
Worldwide |  | 829 |  | 836 |  | (0.9) |  |  | 2,434 |  | 2,622 |  | (7.2) |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 7 |  | 8 |  | (7.9) |  |  | 21 |  | 24 |  | (11.8) |
International |  | 378 |  | 323 |  | 16.9 |  |  | 1,082 |  | 926 |  | 16.8 |
Worldwide |  | 385 |  | 330 |  | 16.4 |  |  | 1,103 |  | 950 |  | 16.1 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 315 |  | 355 |  | (11.0) |  |  | 932 |  | 990 |  | (5.8) |
International |  | 81 |  | 94 |  | (13.6) |  |  | 264 |  | 315 |  | (16.1) |
Worldwide |  | 397 |  | 449 |  | (11.6) |  |  | 1,196 |  | 1,305 |  | (8.3) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4 |  | 3 |  | 57.3 |  |  | 8 |  | 10 |  | (11.0) |
International |  | 42 |  | 54 |  | (21.2) |  |  | 126 |  | 358 |  | (64.7) |
Worldwide |  | 47 |  | 56 |  | (17.5) |  |  | 135 |  | 367 |  | (63.3) |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 750 |  | 713 |  | 5.3 |  |  | 2,381 |  | 2,061 |  | 15.5 |
International |  | 149 |  | 170 |  | (13.1) |  |  | 461 |  | 543 |  | (15.2) |
Worldwide |  | 899 |  | 884 |  | 1.7 |  |  | 2,842 |  | 2,605 |  | 9.1 |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 635 |  | 592 |  | 7.4 |  |  | 1,946 |  | 1,697 |  | 14.7 |
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 635 |  | 592 |  | 7.4 |  |  | 1,946 |  | 1,697 |  | 14.7 |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 115 |  | 121 |  | (5.2) |  |  | 435 |  | 364 |  | 19.4 |
International |  | 149 |  | 170 |  | (13.1) |  |  | 461 |  | 543 |  | (15.2) |
Worldwide |  | 264 |  | 292 |  | (9.8) |  |  | 896 |  | 908 |  | (1.3) |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9,402 |  | 8,871 |  | 6.0 |  |  | 26,655 |  | 24,993 |  | 6.7 |
International |  | 6,161 |  | 5,709 |  | 7.9 |  |  | 17,983 |  | 17,639 |  | 1.9 |
Worldwide |  | 15,563 |  | 14,580 |  | 6.8 |  |  | 44,638 |  | 42,632 |  | 4.7 |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,306 |  | 1,148 |  | 13.8 |  |  | 3,931 |  | 3,292 |  | 19.4 |
International |  | 908 |  | 819 |  | 10.8 |  |  | 2,698 |  | 2,353 |  | 14.6 |
Worldwide |  | 2,213 |  | 1,966 |  | 12.6 |  |  | 6,629 |  | 5,645 |  | 17.4 |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 720 |  | 660 |  | 9.1 |  |  | 2,145 |  | 2,057 |  | 4.3 |
International |  | 698 |  | 619 |  | 12.6 |  |  | 2,064 |  | 1,889 |  | 9.2 |
Worldwide |  | 1,418 |  | 1,279 |  | 10.8 |  |  | 4,209 |  | 3,946 |  | 6.7 |
ABIOMED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 336 |  | 293 |  | 14.5 |  |  | 1,035 |  | 905 |  | 14.3 |
International |  | 86 |  | 68 |  | 26.8 |  |  | 256 |  | 207 |  | 23.9 |
Worldwide |  | 423 |  | 362 |  | 16.8 |  |  | 1,291 |  | 1,112 |  | 16.1 |
SHOCKWAVE(3) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 220 |  | 163 |  | 34.4 |  | 659 |  | 240 |  | *
International |  | 59 |  | 66 |  | (11.2) |  | 169 |  | 66 |  | *
Worldwide |  | 278 |  | 229 |  | 21.2 |  | 828 |  | 306 |  | *
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
OTHER CARDIOVASCULAR |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  | 30 |  | 0.0 |  |  | 93 |  | 89 |  | 4.2 |
International |  | 65 |  | 66 |  | (1.0) |  |  | 209 |  | 192 |  | 9.0 |
Worldwide |  | 95 |  | 96 |  | (0.7) |  |  | 302 |  | 281 |  | 7.5 |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,396 |  | 1,359 |  | 2.7 |  |  | 4,200 |  | 4,229 |  | (0.7) |
International |  | 878 |  | 832 |  | 5.6 |  |  | 2,620 |  | 2,614 |  | 0.3 |
Worldwide |  | 2,274 |  | 2,191 |  | 3.8 |  |  | 6,820 |  | 6,843 |  | (0.3) |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 262 |  | 250 |  | 4.7 |  |  | 796 |  | 785 |  | 1.3 |
International |  | 144 |  | 131 |  | 9.7 |  |  | 440 |  | 435 |  | 1.2 |
Worldwide |  | 405 |  | 381 |  | 6.4 |  |  | 1,235 |  | 1,220 |  | 1.3 |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 216 |  | 212 |  | 2.1 |  |  | 673 |  | 684 |  | (1.5) |
International |  | 160 |  | 140 |  | 14.3 |  |  | 482 |  | 463 |  | 4.0 |
Worldwide |  | 377 |  | 352 |  | 7.0 |  |  | 1,155 |  | 1,147 |  | 0.7 |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 512 |  | 497 |  | 3.0 |  |  | 1,515 |  | 1,499 |  | 1.1 |
International |  | 281 |  | 265 |  | 6.4 |  |  | 818 |  | 786 |  | 4.1 |
Worldwide |  | 793 |  | 761 |  | 4.2 |  |  | 2,333 |  | 2,285 |  | 2.1 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  | 400 |  | 1.3 |  |  | 1,216 |  | 1,262 |  | (3.7) |
International |  | 293 |  | 296 |  | (1.1) |  |  | 881 |  | 930 |  | (5.3) |
Worldwide |  | 698 |  | 696 |  | 0.3 |  |  | 2,096 |  | 2,191 |  | (4.3) |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,031 |  | 983 |  | 4.9 |  |  | 3,076 |  | 2,965 |  | 3.8 |
International |  | 1,511 |  | 1,451 |  | 4.1 |  |  | 4,417 |  | 4,373 |  | 1.0 |
Worldwide |  | 2,542 |  | 2,434 |  | 4.4 |  |  | 7,493 |  | 7,338 |  | 2.1 |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 477 |  | 448 |  | 6.2 |  |  | 1,411 |  | 1,360 |  | 3.7 |
International |  | 688 |  | 661 |  | 4.2 |  |  | 1,991 |  | 1,977 |  | 0.7 |
Worldwide |  | 1,165 |  | 1,109 |  | 5.0 |  |  | 3,402 |  | 3,337 |  | 1.9 |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 555 |  | 535 |  | 3.8 |  |  | 1,666 |  | 1,605 |  | 3.8 |
International |  | 823 |  | 791 |  | 4.0 |  |  | 2,426 |  | 2,397 |  | 1.2 |
Worldwide |  | 1,378 |  | 1,325 |  | 3.9 |  |  | 4,092 |  | 4,001 |  | 2.3 |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 571 |  | 549 |  | 4.2 |  |  | 1,694 |  | 1,619 |  | 4.7 |
International |  | 828 |  | 751 |  | 10.2 |  |  | 2,354 |  | 2,224 |  | 5.8 |
Worldwide |  | 1,400 |  | 1,300 |  | 7.7 |  |  | 4,048 |  | 3,843 |  | 5.3 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 456 |  | 441 |  | 3.5 |  |  | 1,337 |  | 1,288 |  | 3.8 |
International |  | 562 |  | 527 |  | 6.6 |  |  | 1,565 |  | 1,508 |  | 3.8 |
Worldwide |  | 1,018 |  | 968 |  | 5.2 |  |  | 2,902 |  | 2,796 |  | 3.8 |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 116 |  | 108 |  | 7.0 |  |  | 358 |  | 331 |  | 8.0 |
International |  | 266 |  | 225 |  | 18.7 |  |  | 789 |  | 717 |  | 10.1 |
Worldwide |  | 383 |  | 333 |  | 14.9 |  |  | 1,147 |  | 1,048 |  | 9.4 |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,306 |  | 4,038 |  | 6.6 |  |  | 12,902 |  | 12,105 |  | 6.6 |
International |  | 4,124 |  | 3,853 |  | 7.0 |  |  | 12,089 |  | 11,564 |  | 4.5 |
Worldwide |  | 8,430 |  | 7,891 |  | 6.8 |  |  | 24,991 |  | 23,669 |  | 5.6 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 13,708 |  | 12,909 |  | 6.2 |  |  | 39,557 |  | 37,098 |  | 6.6 |
International |  | 10,285 |  | 9,562 |  | 7.6 |  |  | 30,072 |  | 29,203 |  | 3.0 |
Worldwide |  | $23,993 |  | 22,471 |  | 6.8 | % |  | $69,629 |  | 66,301 |  | 5.0 | %
* Percentage greater than 100% or not meaningful (1) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (2) Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025 (3) Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International revenue includes approximately $20 million of sales that should be reflected in the U.S. business. Year-to-date and total Shockwave sales are not impacted, and the amount was immaterial to recast prior year reporting
Operating Profit by Segment of Business |
|  | Fiscal Third Quarter Ended |  |
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  |  |  |  |  |  |  |  |  |  |
|  | Innovative Medicine(1) | MedTech(2) | Total |  | Innovative Medicine(1) | MedTech(2) | Total |  |  |  |  |  |  |  |  |  |  |
Sales to customers |  | $15,563 | 8,430 |  |  | 14,580 | 7,891 |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  | 3,672 | 3,612 |  |  | 3,549 | 3,381 |  |  |  |  |  |  |  |  |  |  |  |
Selling, marketing and administrative |  | 2,869 | 2,801 |  |  | 2,491 | 2,723 |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | 2,944 | 728 |  |  | 4,213 | 739 |  |  |  |  |  |  |  |  |  |  |  |
Other segment items (3) |  | (368) | 2 |  |  | (155) | (11) |  |  |  |  |  |  |  |  |  |  |  |
Segment income before tax |  | $6,446 | 1,287 | 7,733 |  | 4,482 | 1,059 | 5,541 |  |  |  |  |  |  |  |  |  |  |
(Income)/Expense not allocated to segments (4) |  |  |  | 240 |  |  |  | 2,203 |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  | $7,493 |  |  |  | $3,338 |  |  |  |  |  |  |  |  |  |  |
|  | Fiscal Nine Months Ended |  |  |  |  |  |  |  |  |  |
Sales to customers |  | $44,638 | 24,991 |  |  | 42,632 | 23,669 |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  | 11,670 | 10,576 |  |  | 10,522 | 9,749 |  |  |  |  |  |  |  |  |  |  |  |
Selling, marketing and administrative |  | 7,919 | 8,319 |  |  | 7,594 | 7,976 |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | 8,361 | 2,052 |  |  | 9,831 | 2,103 |  |  |  |  |  |  |  |  |  |  |  |
Other segment items (3) |  | (520) | 132 |  |  | (225) | 173 |  |  |  |  |  |  |  |  |  |  |  |
Segment income before tax |  | $17,208 | 3,912 | 21,120 |  | 14,910 | 3,668 | 18,578 |  |  |  |  |  |  |  |  |  |  |
(Income)/Expense not allocated to segments (4) |  |  |  | (6,495) |  |  |  | 5,778 |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  | $27,615 |  |  |  | $12,800 |  |  |  |  |  |  |  |  |  |  |
(1) Innovative Medicine includes: •Intangible amortization expense of $0.6 billion and $0.7 billion in the fiscal third quarter of 2025 and 2024, respectively. Intangible amortization expense of $2.0 billion and $2.1 billion in the fiscal nine months of 2025 and 2024, respectively. •Acquisition and integration related expense of $0.1 billion and $0.3 billion in the fiscal third quarter and fiscal nine months of 2025, respectively, primarily related to the Intra-Cellular acquisition. •Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in the fiscal third quarter and fiscal nine months of 2024. •Litigation expense of $0.4 billion in both the fiscal third quarter and fiscal nine months of 2024, primarily related to Risperdal Gynecomastia. •Monetization of royalty rights of $0.3 billion in the fiscal third quarter and fiscal nine months of 2024. •An In-process research and development impairment of $0.2 billion in the fiscal nine months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020. •A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. (2) MedTech includes: •Intangible amortization expense of $0.5 billion in both the fiscal third quarter of 2025 and 2024. Intangible amortization expense of $1.4 billion and $1.3 billion in the fiscal nine months of 2025 and 2024, respectively. •Acquisition and integration related net expense of $0.1 billion and $0.2 billion in the fiscal third quarter and fiscal nine months of 2025, respectively. Acquisition and integration related expense of $0.3 billion and $0.9 billion, in the fiscal third quarter and fiscal nine months of 2024, respectively, primarily driven by the Shockwave acquisition. •A gain on the sale of securities of $0.2 billion in the fiscal third quarter and fiscal nine months of 2025 •A gain of $0.2 billion related to the Acclarent divestiture in the fiscal nine months of 2024. •A restructuring related charge of $0.2 billion and $0.3 billion in both the fiscal third quarter and fiscal nine months of 2025. A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. Refer to Note 12 for additional details. (3) Other segment expenses for each reportable segment include charges related to other income and expense, restructuring activities and impairment charges related to in-process research and development. (4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal nine months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal third quarter and fiscal nine months of 2024 includes charges for talc matters of $2.0 billion and $5.1 billion, respectively. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal nine months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.
|  | Identifiable Assets
(Dollars in Millions) |  | September 28, 2025 |  | December 29, 2024
Innovative Medicine |  | $74,422 |  | 57,070
MedTech |  | 86,502 |  | 84,322
Total |  | 160,924 |  | 141,392
General corporate (1) |  | 31,892 |  | 38,712
Worldwide total |  | $192,816 |  | 180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
|  | Additions to Property, Plant & Equipment |  | Depreciation and Amortization
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024
Innovative Medicine |  | $1,166 |  | 971 |  | $2,757 |  | 2,793
MedTech |  | 1,674 |  | 1,629 |  | 2,564 |  | 2,370
Segments total |  | 2,840 |  | 2,600 |  | 5,321 |  | 5,163
General corporate |  | 155 |  | 212 |  | 171 |  | 280
Worldwide total |  | $2,995 |  | 2,812 |  | $5,492 |  | 5,443
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | Sales by geographic area
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
United States |  | $13,708 |  | 12,909 |  | 6.2 | % |  | $39,557 |  | 37,098 |  | 6.6 | %
Europe |  | 5,440 |  | 4,914 |  | 10.7 |  |  | 15,937 |  | 15,291 |  | 4.2 |
Western Hemisphere, excluding U.S. |  | 1,231 |  | 1,173 |  | 4.9 |  |  | 3,604 |  | 3,579 |  | 0.7 |
Asia-Pacific, Africa |  | 3,614 |  | 3,475 |  | 4.0 |  |  | 10,531 |  | 10,333 |  | 1.9 |
Total |  | $23,993 |  | 22,471 |  | 6.8 | % |  | $69,629 |  | 66,301 |  | 5.0 | %

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration